Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive randomized double-blind placebo-controlled study of LY3471851 in moderately to severely active ulcerative colitis
MOH_2021-07-07_010125Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing LY3471851 with Placebo (2 arms). Started Jul 2021; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2021-07-07_010125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-07_010125.